Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
- DOI
- 10.1038/s41591-024-03133-0
- Published
- 2024 Oct
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-024-03133-0,
title = {Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.},
author = {Mann JFE and Rossing P and Bakris G and Belmar N and Bosch-Traberg H and Busch R and Charytan DM and Hadjadj S and Gillard P and Górriz JL and Idorn T and Ji L and Mahaffey KW and Perkovic V and Rasmussen S and Schmieder RE and Pratley RE and Tuttle KR},
year = {2024},
journal = {Nature medicine},
doi = {10.1038/s41591-024-03133-0},
url = {https://doi.org/10.1038/s41591-024-03133-0}
}RIS
TY - JOUR TI - Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. AU - Mann JFE AU - Rossing P AU - Bakris G AU - Belmar N AU - Bosch-Traberg H AU - Busch R AU - Charytan DM AU - Hadjadj S AU - Gillard P AU - Górriz JL AU - Idorn T AU - Ji L AU - Mahaffey KW AU - Perkovic V AU - Rasmussen S AU - Schmieder RE AU - Pratley RE AU - Tuttle KR PY - 2024 JO - Nature medicine DO - 10.1038/s41591-024-03133-0 UR - https://doi.org/10.1038/s41591-024-03133-0 ER -
APA
JFE, M., P, R., G, B., N, B., H, B., R, B., DM, C., S, H., P, G., JL, G., T, I., L, J., KW, M., V, P., S, R., RE, S., RE, P., & KR, T. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03133-0
Source records
- pubmed · retrieved 2026-09-26T06:08:05.212Z